PARAMUS, N.J. (May 18, 2023) – An Octapharma-sponsored study published recently in The Journal of Clinical Immunology concludes that cutaquig ® (Immune Globulin Subcutaneous [Human]-hipp, 16.5% ...
image: Octapharma USA presented research at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting evaluating the efficacy and safety of cutaquig® (Immune Globulin Subcutaneous ...
According to FDA, the syringe pumps can cause "serious clinical consequences from lack of flow continuity resulting in delay of therapy, over-infusion or under-infusion," when operating at a rate of ...
Longitudinal study of anti-myeloma treatment patterns in a U.S. commercial population before and after approval of bortezomib (BOR). The utility and prognostic value of positron emission tomography ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results